|Systematic (IUPAC) name|
|Molar mass||422.315[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
NGD-4715 is a drug being developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic, antidepressant and anorectic effects, and it has successfully passed Phase I clinical trials in humans.
|This pharmacology-related article is a stub. You can help ssf by expanding it.|
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
- Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.
- Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007